|
|
||||||||
Guest Access | Sign In via User Name/Password |
|||||||||


* From the Departments of Pneumology (Drs. Cataldo, Bettiol, Bartsch, and Louis) and Biology of Tumor and Development (Drs. Noël and Foidart), University of Liège, Liège, Belgium.
Correspondence to: Didier Cataldo, MD, PhD, Department of Pneumology, CHU Sart-Tilman, 4000 Liège, Belgium; e-mail: Didier.Cataldo{at}ulg.ac.be
Objective: The aim of the study was to determine whether allergen inhalation modulates the levels of matrix metalloproteinase (MMP)-9 and tissue inhibitor of matrix metalloproteinase (TIMP)-1 in the induced sputum recovered from patients during a late-phase reaction.
Method: Eight allergic asthma patients and five healthy control subjects inhaled a dose of Dermatophagoides pteronyssinus extract corresponding to the provocative concentration of the allergen causing a 20% fall in FEV1 and saline solution. Lung function was carefully monitored for 6 h, and an induced sputum test was performed at 6 h after sham challenge or allergen challenge. The total and differential cell counts were analyzed, and the levels of MMP-9 (by enzyme-linked immunosorbent assay [ELISA] and zymography), TIMP-1 (by ELISA), and albumin (by rocket immunoelectrophoresis) were measured.
Results: The sputum eosinophil counts (p < 0.01) and MMP-9 levels (p < 0.05) increased significantly in atopic asthma patients after undergoing the allergen challenge but did not in the control subjects. By contrast, TIMP-1 and albumin levels were not significantly increased in any group. MMP-9 levels, measured after the allergen challenge in asthmatic patients, were significantly correlated with FEV1 variations after allergen inhalation (r = 0.51; p < 0.05) and with the sputum neutrophil percentage (r = 0.71; p < 0.01).
Conclusion: The levels of MMP-9, but not TIMP-1, increase after inhaled allergen challenge in the sputum of allergic asthmatic patients. This protease increase may lead to a transient imbalance between MMP-9 and TIMP-1 favoring proteolytic extracellular matrix degradation.
Key Words: allergen bronchial provocation test asthma matrix metalloproteinases-9
This article has been cited by other articles:
![]() |
M. M. Gueders, M. Balbin, N. Rocks, J.-M. Foidart, P. Gosset, R. Louis, S. Shapiro, C. Lopez-Otin, A. Noel, and D. D. Cataldo Matrix Metalloproteinase-8 Deficiency Promotes Granulocytic Allergen-Induced Airway Inflammation J. Immunol., August 15, 2005; 175(4): 2589 - 2597. [Abstract] [Full Text] [PDF] |
||||
![]() |
F Lose, P J Thompson, D Duffy, G A Stewart, and M-A Kedda A novel tissue inhibitor of metalloproteinase-1 (TIMP-1) polymorphism associated with asthma in Australian women Thorax, August 1, 2005; 60(8): 623 - 628. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. W.S. Ko, C. Diba, M. Roth, K. McKay, P. R.A. Johnson, C. Salome, and G. G. King A Comparison of Airway and Serum Matrix Metalloproteinase-9 Activity Among Normal Subjects, Asthmatic Patients, and Patients With Asthmatic Mucus Hypersecretion Chest, June 1, 2005; 127(6): 1919 - 1927. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Linden, M. Laan, and G. P. Anderson Neutrophils, interleukin-17A and lung disease Eur. Respir. J., January 1, 2005; 25(1): 159 - 172. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Wingett and C. P. Nielson Divergence in NK cell and cyclic AMP regulation of T cell CD40L expression in asthmatic subjects J. Leukoc. Biol., October 1, 2003; 74(4): 531 - 541. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y Oshita, T Koga, T Kamimura, K Matsuo, T Rikimaru, and H Aizawa Increased circulating 92 kDa matrix metalloproteinase (MMP-9) activity in exacerbations of asthma Thorax, September 1, 2003; 58(9): 757 - 760. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |